Capricor Therapeutics Faces Class Action Lawsuit Amid Investment Concerns and Regulatory Challenges

In a significant development for shareholders of Capricor Therapeutics, Inc., a class action lawsuit initiative has begun, targeting investors who acquired shares between December 17, 2025, and July 26, 2026. The law firm Robbins Geller Rudman & Dowd LLP announced that investors who have experienced considerable losses related to their interests in the company have until September 28, 2026, to express their wish to serve as lead plaintiff in the continuing action against the biotechnology firm.

Capricor Therapeutics, based in San Diego and listed on NASDAQ as CAPR, specializes in creating innovative cell and exosome-based therapies primarily aimed at treating Duchenne muscular dystrophy (DMD), a severe genetic disorder that causes progressive muscle degeneration. The firm's leading candidate for treatment, Deramiocel, aims to address complications arising from the condition. However, recent disclosures indicate that regulatory challenges concerning this therapy may place investments at significant risk.

Allegations Against Capricor

The specific allegations outlined in the lawsuit raise serious concerns regarding the integrity of Capricor’s communications to investors about its clinical development processes. Notably, Capricor is accused of failing to disclose that it made alterations to the statistical analysis plan used to evaluate Deramiocel's clinical trial data without appropriate approval from the FDA prior to submitting a Biologics License Application (BLA).

The legal complaint highlights that this lack of communication could potentially mislead investors regarding the effectiveness and safety profile of Deramiocel, especially as the FDA had not agreed to these new methods of data analysis. Investors were substantially impacted when the FDA's briefing materials before its July 29 advisory committee meeting revealed the inadequacies of Capricor’s submissions. These documents reportedly described the changes in the analysis methodology, leading to an unfavorable assessment of Deramiocel's benefit-risk profile. Consequently, such revelations led to a dramatic fall in Capricor's stock price, plummeting by over 64% following the announcements.

The Investor Process

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased or obtained shares during the defined class period is permitted to seek the position of lead plaintiff. This position is typically filled by the investor with the most significant financial interest in the relief sought, who also embodies typical characteristics of the investor class. The lead plaintiff is responsible for representing the interests of all other affected investors and can choose their legal counsel for pursuing claims against Capricor.

Robbins Geller’s track record speaks volumes about its competency in handling such sensitive litigation, having consistently ranked top among law firms specializing in securities fraud. Its focus has been on protecting investor rights and pursuing justice in these types of complex cases. Potential claimants are encouraged to reach out to the firm directly for assistance. Interested investors can fill out a form available through the firm’s website or can contact attorneys Ken Dolitsky or Michael Albert for further details.

Conclusion

The unfolding events surrounding Capricor Therapeutics serve as a crucial reminder for investors about the risks associated with biotechnology investments, particularly in firms that may be navigating turbulent regulatory waters. As the September 28 deadline approaches, those affected by the recent developments must weigh their options carefully and engage with legal counsel to ascertain their rights and interests.

For more information regarding this class action, investors can visit the Robbins Geller law firm’s designated page specific to this case and find key resources and contacts for legal representation.